Oncolytics Biotech Inc SEC filings ONCY
Oncolytics Biotech Inc has 1,000 filings in SEC EDGAR's recent list, going back to Jan 31, 2008. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| AW | Filing | Apr 8, 2026 | — |
| EFFECT | Filing | Apr 3, 2026 | — |
| EFFECT | Filing | Apr 1, 2026 | — |
| CORRESP | Letter to the SEC | Apr 1, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2026 | — |
| 425 | Form 425 | Jan 9, 2026 | — |
| EFFECT | Filing | Dec 9, 2025 | — |
| CORRESP | Letter to the SEC | Dec 5, 2025 | — |
| EFFECT | Filing | Aug 29, 2025 | — |
| CORRESP | Letter to the SEC | Aug 27, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2025 | — |
| SUPPL | Filing | Apr 10, 2025 | — |
| SUPPL | Filing | Aug 5, 2024 | — |
| SUPPL | Filing | Aug 2, 2024 | — |
| EFFECT | Filing | Aug 1, 2024 | — |
| EFFECT | Filing | Jun 17, 2022 | — |
| SUPPL | Filing | Jun 17, 2022 | — |
| SUPPL | Filing | Jun 17, 2022 | — |
| SUPPL | Filing | Mar 5, 2021 | — |
| SUPPL | Filing | Dec 4, 2020 | — |
| SUPPL | Filing | Jun 25, 2020 | — |
| SUPPL | Filing | Jun 16, 2020 | — |
| EFFECT | Filing | Jun 15, 2020 | — |
| SUPPL | Filing | Mar 9, 2020 | — |
| SUPPL | Filing | Jan 3, 2020 | — |
| SUPPL | Filing | Aug 16, 2019 | — |
| SUPPL | Filing | Aug 14, 2019 | — |
| SUPPL | Filing | Aug 13, 2019 | — |
| SUPPL | Filing | Oct 25, 2018 | — |
| SUPPL | Filing | Sep 28, 2018 | — |
| CT ORDER | Filing | Jun 5, 2018 | — |
| SUPPL | Filing | Jun 1, 2018 | — |
| SUPPL | Filing | May 31, 2018 | — |
| CERT | Filing | May 31, 2018 | — |
| 8-A12B | Filing | May 31, 2018 | — |
| EFFECT | Filing | May 7, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2016 | — |
| CORRESP | Letter to the SEC | Oct 14, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2016 | — |
| 25-NSE | Delisting notice | Nov 24, 2015 | — |
| SUPPL | Filing | May 15, 2015 | — |
| SUPPL | Filing | Oct 24, 2014 | — |
| SUPPL | Filing | Oct 23, 2014 | — |
| SUPPL | Filing | Oct 20, 2014 | — |
| SUPPL | Filing | Aug 8, 2014 | — |
| EFFECT | Filing | Aug 4, 2014 | — |
| SUPPL | Supplement | Feb 27, 2014 | — |
| SUPPL | Supplement | Feb 20, 2013 | — |
| SUPPL | Supplement | Feb 19, 2013 | — |
| EFFECT | Filing | Jul 9, 2012 | — |
| SUPPL | Filing | Jun 10, 2010 | — |
| SUPPL | Supplement | Nov 20, 2009 | — |
| SUPPL | Filing | Nov 18, 2009 | — |
| SUPPL | Filing | Nov 18, 2009 | — |
| SUPPL | Supplement | May 12, 2009 | — |
| SUPPL | Filing | May 6, 2009 | — |
| SUPPL | Prospectus supplement dated december 4, 2008 | Dec 4, 2008 | — |
| SUPPL | Prospectus supplement dated december 1, 2008 | Dec 1, 2008 | — |
| EFFECT | Filing | Jun 24, 2008 | — |
Showing 68 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1129928
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.